Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

John W. Shiver, Tong-Ming Fu, Ling Chen, Danilo R. Casimiro, Mary-Ellen Davies, Robert K. Evans, Zhi-Qiang Zhang, Adam J. Simon, Wendy L. Trigona, Sheri A. Dubey, Lingyi Huang, Virginia A. Harris, Romnie S. Long, Xiaoping Liang, Larry Handt, William A. Schleif, Lan Zhu, Daniel C. Freed, Natasha V. Persaud, Liming Guan, Kara S. Punt, Aimin Tang, Minchun Chen, Keith A. Wilson, Kelly B. Collins, Gwendolyn J. Heidecker, V. Rose Fernandez, Helen C. Perry, Joseph G. Joyce, Karen M. Grimm, James C. Cook, Paul M. Keller, Denise S. Kresock, Henryk Mach, Robert D. Troutman, Lynne A. Isopi, Donna M. Williams, Zheng Xu, Kathryn E. Bohannon, David B. Volkin, David C. Montefiori, Ayako Miura, Georgia R. Krivulka, Michelle A. Lifton, Marcelo J. Kuroda, Jörn E. Schmitz, Norman L. Letvin, Michael J. Caulfield, Andrew J. Bett, Rima Youil, David C. Kaslow and Emilio A. Emini ()
Additional contact information
John W. Shiver: Merck Research Laboratories
Tong-Ming Fu: Merck Research Laboratories
Ling Chen: Merck Research Laboratories
Danilo R. Casimiro: Merck Research Laboratories
Mary-Ellen Davies: Merck Research Laboratories
Robert K. Evans: Merck Research Laboratories
Zhi-Qiang Zhang: Merck Research Laboratories
Adam J. Simon: Merck Research Laboratories
Wendy L. Trigona: Merck Research Laboratories
Sheri A. Dubey: Merck Research Laboratories
Lingyi Huang: Merck Research Laboratories
Virginia A. Harris: Merck Research Laboratories
Romnie S. Long: Merck Research Laboratories
Xiaoping Liang: Merck Research Laboratories
Larry Handt: Merck Research Laboratories
William A. Schleif: Merck Research Laboratories
Lan Zhu: Merck Research Laboratories
Daniel C. Freed: Merck Research Laboratories
Natasha V. Persaud: Merck Research Laboratories
Liming Guan: Merck Research Laboratories
Kara S. Punt: Merck Research Laboratories
Aimin Tang: Merck Research Laboratories
Minchun Chen: Merck Research Laboratories
Keith A. Wilson: Merck Research Laboratories
Kelly B. Collins: Merck Research Laboratories
Gwendolyn J. Heidecker: Merck Research Laboratories
V. Rose Fernandez: Merck Research Laboratories
Helen C. Perry: Merck Research Laboratories
Joseph G. Joyce: Merck Research Laboratories
Karen M. Grimm: Merck Research Laboratories
James C. Cook: Merck Research Laboratories
Paul M. Keller: Merck Research Laboratories
Denise S. Kresock: Merck Research Laboratories
Henryk Mach: Merck Research Laboratories
Robert D. Troutman: Merck Research Laboratories
Lynne A. Isopi: Merck Research Laboratories
Donna M. Williams: Merck Research Laboratories
Zheng Xu: Merck Research Laboratories
Kathryn E. Bohannon: Merck Research Laboratories
David B. Volkin: Merck Research Laboratories
David C. Montefiori: Center for AIDS Research, Duke University Medical Center
Ayako Miura: Beth Israel Deaconess Medical Center, Harvard Medical School
Georgia R. Krivulka: Beth Israel Deaconess Medical Center, Harvard Medical School
Michelle A. Lifton: Beth Israel Deaconess Medical Center, Harvard Medical School
Marcelo J. Kuroda: Beth Israel Deaconess Medical Center, Harvard Medical School
Jörn E. Schmitz: Beth Israel Deaconess Medical Center, Harvard Medical School
Norman L. Letvin: Beth Israel Deaconess Medical Center, Harvard Medical School
Michael J. Caulfield: Merck Research Laboratories
Andrew J. Bett: Merck Research Laboratories
Rima Youil: Merck Research Laboratories
David C. Kaslow: Merck Research Laboratories
Emilio A. Emini: Merck Research Laboratories

Nature, 2002, vol. 415, issue 6869, 331-335

Abstract: Abstract Recent studies of human immunodeficiency virus type 1 (HIV-1) infection in humans and of simian immunodeficiency virus (SIV) in rhesus monkeys have shown that resolution of the acute viral infection and control of the subsequent persistent infection are mediated by the antiviral cellular immune response1,2,3,4,5,6,7,8,9,10,11. We comparatively assessed several vaccine vector delivery systems—three formulations of a plasmid DNA vector, the modified vaccinia Ankara (MVA) virus, and a replication incompetent adenovirus type 5 (Ad5) vector—expressing the SIV gag protein for their ability to elicit such immune responses in monkeys. The vaccines were tested either as a single modality or in combined modality regimens. Here we show that the most effective responses were elicited by a replication-incompetent Ad5 vector, used either alone or as a booster inoculation after priming with a DNA vector. After challenge with a pathogenic HIV–SIV hybrid virus (SHIV), the animals immunized with Ad5 vector exhibited the most pronounced attenuation of the virus infection. The replication-defective adenovirus is a promising vaccine vector for development of an HIV-1 vaccine.

Date: 2002
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/415331a Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:415:y:2002:i:6869:d:10.1038_415331a

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/415331a

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().